BACKGROUND: Clinical studies suggest that depression may be accompanied by an activation of the inflammatory response system. We investigated the relation of cytokine interleukin-6 and the acute phase proteins alpha1-antichymotrypsin and C-reactive protein with depression in a population-based study. METHODS: We screened for depressive symptoms 3884 adults at age 60 and older living in a district of Rotterdam, and performed a psychiatric work-up on those who were screened positive. All subjects had blood drawn. We compared levels of inflammation markers adjusted for smoking, stroke, functional disability and cognitive score for 263 cases with depressive symptoms (including 106 subjects with depressive disorders) and 461 randomly selected reference subjects. RESULTS: Age- and gender-adjusted analyses suggested associations of alpha1-antichymotrypsin and C-reactive protein with depressive disorders, but these associations disappeared after adjustment for additional confounding factors. Even after adjustment, increased levels of interleukin-6 were related to depressive disorders (odds ratio per standard deviation increase in interleukin-6 = 1.47; 95% confidence interval = 1.15-1.89). Further analyses demonstrated that this relation was mainly attributable to the subjects with high interleukin-6 concentrations, suggesting a threshold effect. CONCLUSIONS: Interleukin-6 levels were strongly increased in some subjects with depressive disorders, possibly indicating a specific immunologic process. However, the associations of acute phase proteins with depression in this population-based study could be explained by confounding.
BACKGROUND: Clinical studies suggest that depression may be accompanied by an activation of the inflammatory response system. We investigated the relation of cytokine interleukin-6 and the acute phase proteins alpha1-antichymotrypsin and C-reactive protein with depression in a population-based study. METHODS: We screened for depressive symptoms 3884 adults at age 60 and older living in a district of Rotterdam, and performed a psychiatric work-up on those who were screened positive. All subjects had blood drawn. We compared levels of inflammation markers adjusted for smoking, stroke, functional disability and cognitive score for 263 cases with depressive symptoms (including 106 subjects with depressive disorders) and 461 randomly selected reference subjects. RESULTS: Age- and gender-adjusted analyses suggested associations of alpha1-antichymotrypsin and C-reactive protein with depressive disorders, but these associations disappeared after adjustment for additional confounding factors. Even after adjustment, increased levels of interleukin-6 were related to depressive disorders (odds ratio per standard deviation increase in interleukin-6 = 1.47; 95% confidence interval = 1.15-1.89). Further analyses demonstrated that this relation was mainly attributable to the subjects with high interleukin-6 concentrations, suggesting a threshold effect. CONCLUSIONS:Interleukin-6 levels were strongly increased in some subjects with depressive disorders, possibly indicating a specific immunologic process. However, the associations of acute phase proteins with depression in this population-based study could be explained by confounding.
Authors: Bárbara Tagliari; Ana Paula Tagliari; Felipe Schmitz; Aline A da Cunha; Carla Dalmaz; Angela T S Wyse Journal: Neurochem Res Date: 2010-12-24 Impact factor: 3.996
Authors: Álvaro Camacho; Britta Larsen; Robyn L McClelland; Cindy Morgan; Michael H Criqui; Mary Cushman; Matthew A Allison Journal: J Affect Disord Date: 2014-04-19 Impact factor: 4.839
Authors: Micaela Santos; Enikö Kövari; Patrick R Hof; Gabriel Gold; Constantin Bouras; Panteleimon Giannakopoulos Journal: Brain Res Rev Date: 2009-09-08
Authors: Shaoyong Su; Andrew H Miller; Harold Snieder; J Douglas Bremner; James Ritchie; Carisa Maisano; Linda Jones; Nancy V Murrah; Jack Goldberg; Viola Vaccarino Journal: Psychosom Med Date: 2008-12-10 Impact factor: 4.312
Authors: Tasnime N Akbaraly; Eric J Brunner; Jane E Ferrie; Michael G Marmot; Mika Kivimaki; Archana Singh-Manoux Journal: Br J Psychiatry Date: 2009-11 Impact factor: 9.319